First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Clinical trial NCT06625515 · TERMINATED
Trial details
- NCT number
- NCT06625515
- Sponsor
- Accent Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-11
- Primary completion
- 2026-01-09
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.